<p>Alpha Tau Medical（納斯達克代碼：DRTS - 獲取免費報告）預計將在 2025 年 3 月 11 日星期三市場開盤前發佈其 2025 年第四季度的財報。分析師預計該公司將在本季度宣佈每股收益為（$0.13）。個人可以在公司即將發佈的 2025 年第四季度財報頁面上找到會議電話的詳細信息，最新的電話安排定於 2026 年 3 月 13 日星期五東部時間下午 5:00。</p>
<p>獲取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
<h2>Alpha Tau Medical 股價下跌 7.3%</h2>
<p>納斯達克 DRTS 週三開盤價為 $7.07。該公司的市值為 $5.9968 億，市盈率為 -13.60，貝塔值為 1.02。該公司的 50 日簡單移動平均為 $6.80，200 日簡單移動平均為 $4.97。Alpha Tau Medical 的一年低點為 $2.30，一年高點為 $8.60。</p>
<h2>機構投資者對 Alpha Tau Medical 的看法</h2>
<p>機構投資者最近增加或減少了對該公司的持股。Envestnet Asset Management Inc. 在第三季度購買了 Alpha Tau Medical 的新股份，價值 $62,000。美國銀行（Bank of America Corp DE）在第三季度將其在 Alpha Tau Medical 的持股增加了 2,779.1%。美國銀行（Bank of America Corp DE）現在擁有該公司 22,457 股股票，價值 $101,000，此前在該期間又購買了 21,677 股。富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Alpha Tau Medical 的持股增加了 291.7%。富國銀行（Wells Fargo &amp; Company MN）現在擁有該公司 23,500 股股票，價值 $116,000，此前在上個季度又購買了 17,500 股。Millennium Management LLC 在第三季度收購了 Alpha Tau Medical 的新股份，價值約 $170,000。最後，Mariner LLC 在第三季度將其在 Alpha Tau Medical 的持股增加了 185.8%。Mariner LLC 現在擁有該公司 123,250 股股票，價值 $556,000，此前在該期間又購買了 80,129 股。2.65% 的股票由機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>DRTS 最近成為幾份分析師報告的主題。花旗集團（Citigroup）在 12 月 10 日的研究報告中將 Alpha Tau Medical 的目標價從 $8.00 下調至 $7.00，並對該公司給予了 “買入” 評級。HC Wainwright 在 12 月 10 日的研究報告中重申了對 Alpha Tau Medical 股票的 “買入” 評級。Zacks Research 在 2 月 17 日的研究報告中將 Alpha Tau Medical 的評級從 “強烈賣出” 上調至 “持有”。最後，Weiss Ratings 在 1 月 21 日的研究報告中重新發布了對 Alpha Tau Medical 股票的 “賣出（d-）” 評級。有兩位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 $8.00。</p>
<p><strong>獲取我們對 Alpha Tau Medical 的最新分析</strong></p>
<h2>Alpha Tau Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Alpha Tau Medical Ltd. 是一家總部位於以色列內斯齊奧納的醫療技術公司，專注於開發針對實體腫瘤的靶向阿爾法輻射療法。該公司的核心創新被稱為擴散阿爾法發射體輻射療法（DaRT），利用短壽命的放射性同位素直接在腫瘤組織內或附近釋放高能阿爾法粒子。通過利用阿爾法輻射的強大細胞毒性效應，Alpha Tau Medical 旨在提供一種新穎的近距離放射治療方法，可能克服放射抗性並保護周圍健康組織。</p>
<p>該公司的主打產品 Alpha DaRT 目前正在臨牀研究中評估多種適應症，包括複發性或轉移性頭頸癌、皮膚癌和其他實體腫瘤。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們更看好的股票超過 Alpha Tau Medical</li>
<li>新發現的富銅 “克拉肯” 區</li>
<li>美國的 1776 再次發生</li>
<li>你可能想更換財務顧問的 3 個跡象</li>
<li>在東部時間上午 9:30 到 10:45 之間交易</li>
<li>白銀的擠壓正在收緊 - 機會正在形成</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Alpha Tau Medical 嗎？</h2>
<p>在你考慮 Alpha Tau Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Alpha Tau Medical 並不在名單上。</p>
<p>雖然 Alpha Tau Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

富國銀行

美國銀行

DRTS

<p>Alpha Tau Medical（納斯達克代碼：DRTS）將於 3 月 11 日公佈 2025 年第四季度財報，分析師預測每股虧損 0.13 美元。該公司獲得了顯著的機構投資，來自美國銀行和富國銀行的投資尤為顯著。目前，股票市值為 5.9968 億美元，市場共識評級為 “持有”，目標價格為 8.00 美元。Alpha Tau 專注於針對實體腫瘤的靶向α輻射療法，其主要產品 Alpha DaRT 正在進行臨牀評估</p>

<p>Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.</p>
<div class="lb-trans"><p>Alpha Tau Medical（納斯達克代碼：DRTS - 獲取免費報告）預計將在 2025 年 3 月 11 日星期三市場開盤前發佈其 2025 年第四季度的財報。分析師預計該公司將在本季度宣佈每股收益為（$0.13）。個人可以在公司即將發佈的 2025 年第四季度財報頁面上找到會議電話的詳細信息，最新的電話安排定於 2026 年 3 月 13 日星期五東部時間下午 5:00。</p>
</div><p>Get <strong>Alpha Tau Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
</div><h2>Alpha Tau Medical Trading Down 7.3%</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 股價下跌 7.3%</h2>
</div><p>NASDAQ DRTS opened at $7.07 on Wednesday. The firm has a market capitalization of $599.68 million, a price-to-earnings ratio of -13.60 and a beta of 1.02. The firm's 50 day simple moving average is $6.80 and its 200 day simple moving average is $4.97. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60.</p>
<div class="lb-trans"><p>納斯達克 DRTS 週三開盤價為 $7.07。該公司的市值為 $5.9968 億，市盈率為 -13.60，貝塔值為 1.02。該公司的 50 日簡單移動平均為 $6.80，200 日簡單移動平均為 $4.97。Alpha Tau Medical 的一年低點為 $2.30，一年高點為 $8.60。</p>
</div><h2>Institutional Investors Weigh In On Alpha Tau Medical</h2>
<div class="lb-trans"><h2>機構投資者對 Alpha Tau Medical 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical during the third quarter valued at $62,000. Bank of America Corp DE increased its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo &amp; Company MN raised its position in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo &amp; Company MN now owns 23,500 shares of the company's stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Millennium Management LLC acquired a new position in Alpha Tau Medical during the 3rd quarter worth about $170,000. Finally, Mariner LLC lifted its holdings in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company's stock worth $556,000 after buying an additional 80,129 shares during the period. 2.65% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。Envestnet Asset Management Inc. 在第三季度購買了 Alpha Tau Medical 的新股份，價值 $62,000。美國銀行（Bank of America Corp DE）在第三季度將其在 Alpha Tau Medical 的持股增加了 2,779.1%。美國銀行（Bank of America Corp DE）現在擁有該公司 22,457 股股票，價值 $101,000，此前在該期間又購買了 21,677 股。富國銀行（Wells Fargo &amp; Company MN）在第四季度將其在 Alpha Tau Medical 的持股增加了 291.7%。富國銀行（Wells Fargo &amp; Company MN）現在擁有該公司 23,500 股股票，價值 $116,000，此前在上個季度又購買了 17,500 股。Millennium Management LLC 在第三季度收購了 Alpha Tau Medical 的新股份，價值約 $170,000。最後，Mariner LLC 在第三季度將其在 Alpha Tau Medical 的持股增加了 185.8%。Mariner LLC 現在擁有該公司 123,250 股股票，價值 $556,000，此前在該期間又購買了 80,129 股。2.65% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>DRTS has been the subject of several recent analyst reports. Citigroup cut their target price on Alpha Tau Medical from $8.00 to $7.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, December 10th. HC Wainwright restated a &#34;buy&#34; rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Zacks Research upgraded Alpha Tau Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>DRTS 最近成為幾份分析師報告的主題。花旗集團（Citigroup）在 12 月 10 日的研究報告中將 Alpha Tau Medical 的目標價從 $8.00 下調至 $7.00，並對該公司給予了 “買入” 評級。HC Wainwright 在 12 月 10 日的研究報告中重申了對 Alpha Tau Medical 股票的 “買入” 評級。Zacks Research 在 2 月 17 日的研究報告中將 Alpha Tau Medical 的評級從 “強烈賣出” 上調至 “持有”。最後，Weiss Ratings 在 1 月 21 日的研究報告中重新發布了對 Alpha Tau Medical 股票的 “賣出（d-）” 評級。有兩位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 $8.00。</p>
</div><p><strong>Get Our Latest Analysis on Alpha Tau Medical</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Alpha Tau Medical 的最新分析</strong></p>
</div><h2>Alpha Tau Medical Company Profile</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd. 是一家總部位於以色列內斯齊奧納的醫療技術公司，專注於開發針對實體腫瘤的靶向阿爾法輻射療法。該公司的核心創新被稱為擴散阿爾法發射體輻射療法（DaRT），利用短壽命的放射性同位素直接在腫瘤組織內或附近釋放高能阿爾法粒子。通過利用阿爾法輻射的強大細胞毒性效應，Alpha Tau Medical 旨在提供一種新穎的近距離放射治療方法，可能克服放射抗性並保護周圍健康組織。</p>
</div><p>The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.</p>
<div class="lb-trans"><p>該公司的主打產品 Alpha DaRT 目前正在臨牀研究中評估多種適應症，包括複發性或轉移性頭頸癌、皮膚癌和其他實體腫瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Alpha Tau Medical</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Trade this between 9:30 and 10:45 am EST</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Alpha Tau Medical</li>
<li>新發現的富銅 “克拉肯” 區</li>
<li>美國的 1776 再次發生</li>
<li>你可能想更換財務顧問的 3 個跡象</li>
<li>在東部時間上午 9:30 到 10:45 之間交易</li>
<li>白銀的擠壓正在收緊 - 機會正在形成</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJUUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRTS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alpha Tau Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Alpha Tau Medical 嗎？</h2>
</div><p>Before you consider Alpha Tau Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Alpha Tau Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Alpha Tau Medical 並不在名單上。</p>
</div><p>While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Alpha Tau Medical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Wednesday

- Alpha Tau Medical 將於 3 月 11 日公佈 2025 年第四季度業績，預計每股收益為（$0.13）。  
- 股價現報 $7.07，市值為 $599.68 百萬，分析師對該股票的評級以 “持有” 居多。  
- 公司正在開發靶向 α 輻射療法，以治療固體腫瘤，目前正進行臨牀研究。

Alpha Tau Medical (DRTS) 預計將在週三宣佈季度財報